Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $175 and keeps an Equal Weight rating on the shares. The ...

Baird raised the firm’s price target on Quest Diagnostics (DGX) to $194 from $191 and keeps an Outperform rating on the shares. Stay Ahead of ...

Baird analyst Eric Coldwell maintained Quest Diagnostics with an Outperform rating and raised the price target from $191 to ...

in a research report on Tuesday, March 4th. UBS Group boosted their price target on Quest Diagnostics from $166.00 to $170.00 and gave the company a “neutral” rating in a report on Monday ...

Return on Equity (ROE): Quest Diagnostics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.24%, the company may encounter ...

Redburn Atlantic began coverage on Quest Diagnostics in a report on Wednesday, April 2nd. They set a “buy” rating and a $195.00 price target for the company. Redburn Partners set a $195.00 ...

QUEST DIAGNOSTICS ($DGX) is expected to release its quarterly earnings data on Tuesday, April 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

QUEST DIAGNOSTICS ($DGX) posted quarterly earnings results on Tuesday, April 22nd. The company reported earnings of $2.21 per share, beating estimates of $2.17 by $0. ...

Q1 2025 Earnings Call Transcript April 22, 2025 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is ...

This drop was worse than the S&P 500’s 10% fall. BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

This drop was worse than the S&P 500’s 10% fall. BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.